Full Year Results 

AstraZeneca dips on earnings miss

AstraZeneca dips on earnings miss

While AstraZeneca (AZN) exceeded expectations in its third quarter, slower momentum at the end of the year put a dampener on the full-year picture. Product sales increased by 9 per cent on a constant currency increase to $6.3bn (£4.85bn) in the three months to 31 December, half the rate seen in the previous quarter. Flat adjusted earnings per share of 350¢ in 2019 came in below analyst consensus of 360¢.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now